

HETEROCYCLES, Vol. 81, No. 7, 2010, pp. 1571 - 1602. © The Japan Institute of Heterocyclic Chemistry
Received, 11th March, 2010, Accepted, 28th April, 2010, Published online, 28th April, 2010
DOI: 10.3987/REV-10-671

CHEMISTRY AND BIOLOGICAL ACTIVITIES OF VIBSANE-TYPE DITERPENOIDS

Yoshiyasu Fukuyama,* Miwa Kubo, Tomoyuki Esumi, Kenichi Harada, and
Hideaki Hioki

Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro-cho,
Tokushima 770-8514, Japan

Abstract – This review focuses on the structural diversity, biological activities and synthesis of vibsane-type diterpenoids. Vibsane-type diterpenoids are considered to be rarely occurring natural products because they have been found exclusively in a few *Viburnum* species such as *V. awabuki*, *V. odoratissimum*, and *V. suspensum*. These diterpenoids are further classified into 11-membered ring, 7-membered ring, and rearranged (neovibsanin) types, and therefore, their chemical diversity forms a unique chemical library. We describe the absolute stereochemistry of the typical 11-membered ring vibsanins B and F, a variety of vibsane-type diterpenoids, the chemical correlations between the three subtypes, their biological activities, and the synthesis of vibsanin F and neovibsanin B.

INTRODUCTION

The genus *Viburnum* consists of about 150 species of shrubs or small trees that were previously included in the family Caprifoliaceae. However, recent classifications based on molecular phylogeny have put them in the family Adoxaceae.¹ They are distributed in the temperate Northern Hemisphere, with a few species extending into tropical regions in South America and Southeast Asia, and about 15 species are distributed in Japan.² There is a long history of the folk medicinal use of *Viburnum* species. For example, the dried bark of *V. opulus*, which is known as "Cramp Bark," is used to alleviate painful menstrual cramps as well as a sedative.³ Native American women took black haw (*V. prunifolium*) to treat the menopause and menstrual cramps.⁴ The genus *Viburnum* has been documented to contain a variety of compounds such as iridoids, terpenoids, and aromatic compounds.^{5, 6} Among the chemical contents of *Viburnum* species, vibsane-type diterpenoids are considered to be characteristic of the *Viburnum* species because they have not been found in other higher plants. In this review, we focus on the structural diversity, biological activities and synthesis of vibsane-type diterpenoids.

1. Vibsane-type diterpenoids

In 1980, Kawazu reported the isolation of vibsane-type diterpenoids from the leaves of *Viburnum awabuki*, and they were shown to consist of a unique fumulane skeleton with an additional C5 unit (Figure 1).




Figure 1. Carbon skeletons of fumulane and vibsane




Figure 2. Vibsanins A–F, which were isolated from *Viburnum awabuki* by Prof. Kawazu

However, there has been little interest in their chemical structure and biological activity since their discovery. Since 1996, we have continued to investigate the vibsane-type diterpenoids that are specific to *Viburnum* species and their biological activities, resulting in the discovery of about 60 new diterpenoids. They possess unique structures, some of which have unexpected chemical reactivity and interesting biological activity. The first vibsane-type diterpenoids that were reported by Kawazu were vibsanins A

(17), B (1), and F (3), which possess an 11-membered ring, and vibsanins C (2) – E (16), which have a 7-membered ring (Figure 2).⁷ Their stereochemistry has remained unexplored except for that of vibsantin E (16).⁸ Since these diterpenoids consist of a new carbon skeleton, we have proposed the new term of “Vibsane” for diterpenoids possessing a fumulane carbon framework with an additional isoprene unit.⁹

2.1. The stereochemistry of vibsanins B (1) and C (2)¹¹

It was necessary to determine the absolute stereochemistry of vibsanins B (1) and C (2) before discussing the structures of the newly isolated vibsane-type diterpenoids. The ¹H NMR of 1 showed two kinds of broad signals at room temperature, but a pair of the sharp signals was observed at 0°C. This phenomenon indicated that vibsantin B (1) is present in solution as two conformational isomers.





Figure 3. The two conformers, **1a** and **1b**, elucidated by NOESY, and the lowest energy conformers **CT** and **BC** obtained by MM2 calculations. The arrows show the NOE

Two conformers, **1a** and **1b**, were elucidated on the basis of NOESY data and *J* values (Figure 3). The main conformer, **1a**, demonstrated the NOE correlations shown in Figure 3 and had a high *J*_{8,9} (9.3 Hz) value. These NMR data suggested that **1a** adopts a chair-like conformation for the sequential bonds from C-5 to C-10 with a dihedral angle of 180° between C8-H and C9-H and takes a *transoid* geometry for the α,β-unsaturated ketone at C4–C6, whereas **1b** consists of a boat conformation and has a *cisoid* form according to NOE analysis and its small *J*_{8,9} (2.2 Hz). Additionally, **1a** and **1b** were consistent with the two most stable conformers, **CT** and **BC**, found by the MM2 calculations.³¹ In the course of the VT (variable temperature) experiments for **1** in DMSO-*d*₆, we found that **1** induced an irreversible change at

110°C. To elucidate this thermal transformation in detail, a solution of **1** in toluene was refluxed for 1 h to give rise to four products, which eventually were found to correspond to 7-membered ring vibsanin C (**2**) (85.9%) and its stereoisomers **2a** (11.2%), **2b** (1.6%), and **2c** (0.2%) (Scheme 1). Vibsanin C (**2**) and 5-*epi*-vibsanin C (**2b**) are natural products, but **2a** and **2c** have been not found in nature. The formation of the four 7-membered ring vibsanins can be ascribed to the *oxy*-Cope rearrangement of **1**. The major product, vibsanin C (**2**), and its 5-epimer, **2b**, which contains a $\Delta^{8,9}$ *E* olefin, are considered to rearrange through the **CT** and **BC** conformers, respectively; whereas, **2a** and **2c**, which contain $\Delta^{8,9}$ *Z* olefin, are presumably transformed through the **CC** and **BT** conformers, which were found to be within 6 kcal/mol of the global minimum energy by MM2 calculations (Figure 4).



Scheme 1. *Oxy*-Cope rearrangement of vibsanin B (**1**)






Figure 4. **CC** and **BT** conformers leading to **2a** and **2c**, respectively



Scheme 2. Conversion of **2** to the *p*-bromophenyl carbamate derivative **2e** and an ORTEP diagram of the molecular structure of **2e**

Thus, the absolute configuration of the 11-membered ring vibsanin B (**1**) was completely correlated with that of the 7-membered ring vibsanin C (**2**) via an *oxy*-Cope rearrangement. Next, the enol ester of **2** was saponified under basic conditions, which was followed by an intramolecular aldol condensation reaction to give rise to the aldehyde **2d**, which was converted to the bromophenyl carbamate **2e**. X-ray crystallographic analysis of **2e** unambiguously established the absolute 5*S*, 10*R*, and 11*S* configurations of vibsanin C (**2**) (Scheme 2). This result means that vibsanin B (**1**) has chiral centers of 7*R*, 8*R*, and 11*S*. Thus, the absolute structures of **1** and **2**, which were previously unsolved, have been established (Figure 5).




Figure 5. Absolute configurations of vibsanins B (**1**) and C (**2**)

2.2. Determination of the absolute configuration of vibsanin F (**3**) by synthesis¹²

Although vibsanin F (**3**), which was isolated from the leaves of *V. awabuki* in 1980, belongs to the simplest 11-membered ring form of the vibsane-type diterpenoids, its stereochemistry has never been solved.⁷ We have decided to unambiguously determine the absolute stereochemistry of **3** via its asymmetric synthesis. Vibsanin F (**3**) has three chiral centers, among which C-7 and C-11 are anticipated to be *7S* and *11S*, respectively, based on those of vibsanin B (**1**) as shown in Figure 6. However, the chirality of C-6 may be **3a** (*6S*) or **3b** (*6R*).





Figure 6. Possible structures of **3a** and **3b** for vibsanin F (**3**)

First, we selected **3a** as the first synthetic target. The synthetic procedures used are outlined in Schemes 3 and 4. Asymmetric epoxidation of the allyl alcohol **4** by the Sharpless protocol¹³ provided **5**, which had *6S* and *7S* chiral centers that corresponded to those of **3a**. Regioselective epoxidation of **5** with *m*-chloroperbenzoic acid exclusively gave the diepoxide **6** as a diastereomeric mixture. The primary hydroxyl group of **6** was converted to its triflate, with which a large excess of the dianion of methyl acetoacetate was reacted at 0°C to give rise to **7** in high yield. The introduction of a 4-methyl-3-pentenyl unit using sodium hydride and 15-crown-5 in DMSO gave rise to the precursor **8** in good yield, which was required for the subsequent palladium-catalyzed macrocyclization. Subjecting **8** to the Tsuji-Trost reaction using 10 mol% Pd(PPh₃)₄ in DMSO afforded the sole product **9** in a moderate yield.¹⁴ The stereoselective formation of **9** can be explained by assuming that transition states **A** and **B**, as shown in Figure 7, are involved in this cyclization. If the nucleophilic displacement of the π -allylpalladium intermediate with the anion of the β -ketoester moiety proceeds through a product-like transition state, transition state **A**, which should lead to the more stable product **9** with a pseudoequatorial C6 unit and a pseudoaxial methyl group, probably favors over transition state **B**, producing a less stable product with the opposite stereochemistry at the quaternary center.



Scheme 3. Reagents and conditions: a) $\text{Ti}(\text{OiPr})_4$, L-(+)-DET, TBHP, MS4A, CH_2Cl_2 , -35°C , 99% (92% ee); b) MCPBA, CH_2Cl_2 , 0°C , 91%; c) Tf_2O , Et_3N , THF, -78°C , then 5 eq. the dianion of methyl acetoacetate generated with NaH and $n\text{BuLi}$, THF, 0°C , 94%; d) NaH, 15-crown-5, DMSO, then 5-iodo-2-methylpent-2-ene, 77%; e) 10 mol% $\text{Pd}(\text{PPh}_3)_4$, DMSO, 90°C , 60%.





Figure 7. Possible transition states, **A** and **B**, for palladium-catalyzed cyclization of **8**

Although the 11-membered ring was diastereoselectively constructed, the *Z*-geometry of the trisubstituted olefin in **9** has to be converted to *E*-geometry. First, the alcohol **9** was protected with TBDMSCl, before the reduction of both carbonyl groups with LiAlH_4 to give rise to the diol **10**, which was then mesylated (Scheme 4). The resultant dimesylate was subjected to elimination of the secondary mesylate under basic conditions, giving rise to the monomesylate **11** in a moderate yield over three steps. Subsequent reductive demesylation of **11** was successfully achieved using a NaBH_4 -DMPU system, resulting in the formation of **12** in good yield. The aldehyde **13**, which was derived from **12**, was treated with AIBN and thiophenol

to produce the desired *E*-olefin **14**. Finally, the conjugate aldehyde in **14** was reduced by the Luche protocol to afford **3a**. The ^1H NMR of **3a**, however, was not identical to that of natural vibsanin F (**3**). Thus, each epoxide ring of the synthetic product **3a** and vibsanin F was reduced with LiAlH_4 , resulting in the preparation of the same diol **15**. All the spectroscopic data for both diols were identical to each other, and therefore, the absolute configuration of vibsanin F has been established to be **3b** with *6R*, *7S*, and *11S* forms.



Scheme 4. Reagents and conditions: a) TBDMSCl, Et_3N , 4-DMAP, CH_2Cl_2 , 74%; b) LiAlH_4 , THF, 0°C ; c) MsCl , Et_3N , 4-DMAP, CH_2Cl_2 , 0°C ; d) DBU, toluene, 120°C , 60% over three steps; e) NaBH_4 , DMPU, 55°C ; f) TBAF, THF, 100%; g) Dess-Martin periodinane, Et_3N , CH_2Cl_2 , 100%; h) PhSH , AIBN, benzene, 90°C , 48%; i) NaBH_4 , CeCl_3 , MeOH , 0°C , 56%.

2.3. 11-Membered ring vibsanine-type diterpenoids

Vibsanine-type diterpenoids consist of three sub-types, 11-membered ring, 7-membered ring, and the rearranged types. These diterpenoids occur exclusively in *V. awabuki*, *V. odratissimum*, *V. suspensum*, and *V. sieboldi*. The 11-membered ring and 7-membered ring vibsanine-type diterpenoids are common to these plants. Most 11-membered ring vibsanins consist of a fumulane-like skeleton containing a β , β -dimethylacrylate group at the C-8 position except for vibsanin F (**3**). Vibsanin A (**17**)⁷ and vibsanins P (**18**) – T (**22**),¹⁵ which contain oxidatively modified C6 units at the C-11 position, were isolated from both

Japanese and Taiwanese *V. odoratissimum*.

Since the conformations of the 11-membered ring vibsanins A and P – T, which bear a 6,7-epoxide ring, are fixed, analysis of their NMR can be performed normally. On the other hand, vibsanin B (**1**) and vibsanols A (**23**) and B (**24**),¹⁶ which contain a cross-conjugated diene, show complex NMR signals due to the presence of several kinds of conformational isomers. Therefore, careful structure elucidation should be performed by a combination of VT NMR experiments and MM2 calculations.¹¹




Figure 8. 11-Membered ring vibsanins

2.4. 7-Membered ring vibsane-type diterpenoids

The 7-membered ring vibsanins are made up of a diverse range of compounds, which possess two ketones and an isoprene unit attached to the 7-membered ring. There are two basic types, the (5*S*,10*R*) and (5*R*,10*R*) stereoisomers. Vibsanins C (**2**), G (**25**), H (**27**), and 18-*O*-methylvibsanin G (**26**), which belong to the (5*S*,10*R*) type, occur commonly in *Viburnum* species.^{17, 18} Vibsanins I (**30**), J (**31**), K (**32**), and 18-*O*-methylvibsanin K (**33**)¹⁹ as well as 14,15-epoxyvibsanin C (**34**) were isolated from *V. awabuki* in Tokushima^{17,19} and *V. awabuki* in Taiwan, respectively. On the other hand, 5-*epi*-vibsanins C (**35**), H (**36**), I (**38**), K (**39**) and their 18-*O*-methyl and/or 15-*O*-methyl congeners **37** and **40**²⁰ have been found in all

Viburnum species except for *V. suspensum*. Vibsananin M (**41**), which possesses a $\Delta^{4,5}$ double bond¹⁸ and the bicyclic vibsananin N (**46**)²¹ were isolated from *V. odoratissimum* and *V. awabuki* in Taiwan. Furthermore, aldovibsanins A (**42**) – C (**45**) were isolated from *V. odoratissimum*.^{22, 18}




Figure 9. 7-Membered ring vibsananins

Additionally, interesting tricyclic 7-membered vibsananins are known (Figure 10). Vibsananin E (**16**) and 16-hydroxyvibsananin E (**47**),²³ which were isolated from *V. awabuki*, have an ether bond between C-15 and C-18; whereas, cyclovibsanin A (**48**) and 15-*O*-methylcyclovibsanin A (**49**), 15-*O*-methylcyclovibsanin B (**50**), and 3-hydroxy-15-*O*-methylcyclovibsanin A (**51**), which are composed of a tricyclo[6.3.2.0^{0,0}]tridecane skeleton, contain C-C bonds between C-18 and C-16 or C-17. Cyclovibsanins have no oxygen atoms between C-18 and C-15.²⁴





Figure 10. 7-Membered ring tricyclic vibsanins



Scheme 5. Conversion of vibsanin C (**2**) to vibsanin E (**16**) and a plausible biosynthetic pathway for cyclovibsanins

Vibsanin E (**16**) can be readily converted from vibsanin C (**2**) via a cationic process (a) by treating it with $BF_3 \cdot OEt_2$ as shown in Scheme 5.²³ On the other hand, another plausible biosynthetic pathway for cyclovibsanins is (b) shown in Scheme 5, in which a proton is eliminated from one of two methyl groups in **52** to give rise to **52a**. Dehydration produces the exomethylene ketone **52b**, the C-4 carbonyl group of which is then protonated to trigger cyclization through the cationic intermediate **52b**, resulting in the formation of a tricyclic framework such as that seen in the cyclovibsanins.

Furanovibsanins, a diverse range of 7-membered ring vibsanins, which are presumed to be produced by two ketones at the C-4 and C-7 positions, have also been found (Figure 11). The examples shown are furanovibsanin A (**53**) and its 3-*O*-methyl congener **54**, which is derived from 3-hydroxyvibsanin E (**47**). The additional examples are furanovibsanin B (**55**) and its 7-epimer **56**, and furanovibsanins C (**57**) – G

(61). These diterpenoids were isolated from *V. awabuki* collected in Tokushima.²⁵




Figure 11. 7-Membered ring furanovibsanins

2.5. Rearranged vibsanine-type diterpenoids (neovibsanins)

The rearranged vibsanine-type diterpenoids (neovibsanins), which contain a β , β -dimethylacrylate ester and an isoprene unit-substituted cyclohexene ring core fused to a tetrahydrofuran ring, are rarely occurring natural products (Figure 12). In 1996, the first rearranged vibsanine-type diterpenoids, neovibsanins A (62) and B (63), were isolated from *V. awabuki*.¹⁰ Recently, we have ascertained the presence of neovibsanin (86) in the fresh leaves of *V. awabuki* and also found that neovibsanin is changed to neovibsanins A (62) and B (63) when kept in methanol at room temperature, indicating that neovibsanins A and B are artifacts derived from neovibsanin.¹⁹ Since neovibsanins A (62) and B (63) were reported, a number of rearranged vibsanine-type diterpenoids have been found in *V. awabuki*, *V. suspensum*, and *V. sieboldi*, and have become known as a characteristic compound group of the *Viburnum* species as summarized in Figure 12.





Figure 12. Rearranged vibsane-type diterpenoids (neovibsanins)


Among them, neovibsanin C (**64**) is the first example of a natural product with a macrocyclic structure formed through an *endo*-peroxide group.²⁶ The unusual structure of **64** was established by converting it from neovibsanin B (**63**) as outlined in Scheme 6. The reduction of **64** with Zn in EtOH-AcOH resulted in



Scheme 6. Chemical correlation of neovibsanin B to neovibsanin C

the formation of the diol **83**, which was treated with methanol under acidic conditions to give rise to the methyl acetal **84**. The acetal **84** was also derived from neovibsanin B (**63**) by photosensitized oxidation, followed by reduction of the formed peroxy group [**7-*epi*-neovibsanin D (**66**)**]. In addition, when **66** was treated with *p*TsOH in anhydrous benzene, **64** was generated in good yield, presumably by an acetal exchange reaction. Thus, the structure of neovibsanin C (**64**) including its absolute configuration was established.

Neovibsanins H (**67**) and I (**69**),²⁸ and their 2-*O*-methyl congeners **68** and **70** are neovibsanins that do not possess an acetal group. Similar compounds containing an additional 6-membered ring [neovibsanins F (**71**) and its 14-*epimer* **73**, and 14-*epi*-18-oxoneovibsanin F (**74**)] were isolated from *V. suspensum*.²⁸ Spirovibsanin A (**82**) is the first example of a *nor*-vibsanine-type diterpenoid.²⁹ Recently, neovibsanins J (**79**), K (**80**), and P (**81**), in which two hydroxy groups at the C-4 and C-18 positions are involved in acetal formation on the C-7 carbonyl, were found.³⁰



Scheme 7. Photochemical reaction of vibsanin B (**1**)

It has been shown that a 7-membered ring vibsanin C (**2**) can be derived from vibsanin B (**1**), an 11-membered ring vibsanine-type diterpenoid, by thermal *oxy*-Cope rearrangement. However, no formation of neovibsanins was observed even upon heating **1** under acidic or basic conditions. It should be noted

that neovibsanins A (**62**) and B (**63**) can be produced from vibsanin B (**1**) by photochemical reaction. Surprisingly, irradiation of vibsanin B (**1**) in benzene with a high pressure Hg lamp afforded **87**, which possesses a neovibsanin-framework, in 4% yield, along with **85** (18%) and **2c** (27%) (Scheme 7).¹⁰ These compounds have been neither found in natural sources. When the photochemical reaction of **1** was carried out in MeOH, neovibsanins A (**62**) and B (**63**) were produced in 12% and 20% yields, respectively, in addition to **88** (9%) and **89** (8%) as over-reacted products.²⁷ The generation of **88** and **89** was presumably due to a series of fragmentation and cationic cyclizations triggered by the methanolysis of a β,β -dimethylacryl ester group.²⁷ Furthermore, irradiation of **1** in 50% aqueous MeOH for 1 h directly yielded neovibsanin (**86**). This photochemical reaction of **1** forces the *E/Z* isomerization of the double bond at C-5 to generate (5*Z*)-vibsanin B (**85**). The MM2 calculations for **85** and **1**, in which the C12–C17 side chain was replaced with a *t*-butyl group, were performed using MacroModel®³¹ and provided the most stable conformers, **1**-(5*Z*) and **1**-(5*E*), for each molecule as shown in Figure 13. In the case of **1**-(5*Z*), the distance between the C-4 carbonyl and the C-7 OH is 1.65 Å, whereas **1**-(5*E*) has a distance of 4.98 Å as depicted in Figure 13. This means that a 1,7-hydrogen shift from the OH group at C-7 to the carbonyl at C-4 occurs in **1**-(5*Z*), but not in **1**-(5*E*). This hydrogen shift not only causes a breakage of the C-7/C-8 bond as well as cyclization between C-10 and C-4, leading to the neovibsanin-framework, but also undergoes another *oxy*-Cope rearrangement via **1a** to give rise to a 7-membered ring (8*Z*)-10-*epi*-vibsanin C (**86**), which is not formed by the thermal *oxy*-Cope rearrangement of vibsanin B (**1**).





Figure 13. The most stable conformers, **1**-(5*Z*) and **1**-(5*E*), for (5*Z*)-vibsanin B (**85**) and vibsanin B (**1**), respectively, obtained by MM2 calculation

Taking the aforementioned results into consideration, we wish to propose plausible biosynthetic mechanisms for neovibsanins, as outlined in Scheme 8. The biosynthesis of all neovibsanins starts from the key intermediate **A**, which is derived from vibsanin B (**1**). The C-18 hydroxy group undergoes 1,4-addition to yield **B**. In the case of route **a**, a hemiacetal **E** is generated, leading to neovibsanins A–D. Likewise, route **b** gives the intermediate allyl cation **C** prior to dehydration, which is trapped by some nucleophiles such as water to afford neovibsanins H–I (route **c**) and causes cationic cyclization to give **D**, resulting in the formation of neovibsanins F–G (route **d**). Additionally, neovibsanins J–K are presumably converted from the key intermediate **A** via the production of a bicyclic acetal of the C-7 carbonyl containing C-18 and C-4 hydroxy groups.³⁰ However, a question still remains about how the key intermediate **A** is generated from vibsanin B (**1**) by enzyme-catalyzed reaction.



Scheme 8. Plausible biosynthetic pathways for the formation of various neovibsanins from vibsanin B (**1**)

3. Biological activities of vibsane-type diterpenoids

The leaves of *V. awabuki* have been used as a fish poison for catching fishes in Okinawa and Southeast Asia for a long time. In 1980, Kawazu reported the first isolation of a piscicidal compound, vibsanin A, and a plant growth inhibitor, vibsanin B (**1**).⁷ Later, many vibsane-type diterpenoids were reported,

among which some diterpenoids such as vibsantin C (**2**), 5-*epi*-vibsantin C (**35**),²⁰ vibsanol A (**23**),¹⁶ and vibsantins K (**32**) and P (**18**)^{18, 32} exhibited significant and/or moderate cytotoxicity against tumor cells. Additionally, vibsantin B (**1**) and neovibsantin F (**71**) showed moderate toxic activity in a brine shrimp lethality assay.²⁸

3.1 Neurotrophic activities of neovibsantins

A remarkable pathological symptom of Alzheimer's disease (AD) is the loss of neuronal cells in the brain. Correspondingly, the overall strategy for treatment of AD is to prevent neuronal death or to produce new neuronal cells in the degenerative regions. Neurotrophins, such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3) and glial cell line-derived neurotrophic factor (GDNF), are recognized as important regulatory substances in the nervous system.³³ Thus, neurotrophins are expected to have therapeutic efficacy for the treatment of AD. However, they can not cross brain-blood barrier because of the properties of its high molecular polypeptide and are easily metabolized by peptidases under physiological conditions.³⁴ To address this issue, considerable efforts have been made to find small molecules that have neurotrophic properties or are capable of enhancing the action of NGF in appropriate cell populations.³⁵ Rat pheochromocytoma (PC12) cells have been used as a good *in vitro* model of neuronal differentiation. After stimulation with NGF, PC12 cells differentiate to extend neurites and develop the characteristics of sympathetic neurons.⁴⁰ For example, two iridoids, picrosides I and II³⁴ and some clerodane-type diterpenoids, 6 α ,7 α -dihydroxyannonene, and 7 α ,20-dihydroxyannonene³⁷ have been demonstrated to show neurite outgrowth-promoting activity in NGF-mediated PC12 cells. Also some synthetic compounds, *N*-benzyloxycarbonyl-Leu-Leu-leucinal (ZLLLal),³⁸ AIT-082,³⁹ SR57746,⁴⁰ and Aroclor 1254,⁴¹ have been reported to accelerate the action of NGF in PC12 cells. Recently, we have found that neovibsantin (**86**), and neovibsantins A (**62**) and B (**63**) have neurotrophic properties. Namely, they promote neurite outgrowth of NGF-mediated PC12 cells at concentrations ranging from 10 μ M to 40 μ M.^{42,43}

Evaluation was carried out for PC12 cells neurite outgrowth according to a previously reported experiment procedure.^{40,44} As shown in Figure 14, neovibsantin (**B**), neovibsantin A (**C**) and neovibsantin B (**D**) significantly promoted neurite outgrowth from NGF (10 ng/mL)-treated PC12 cells at 40 μ M. Among three compounds, neovibsantin A seems less potent than neovibsantin and neovibsantin B. However, all of them had no effect on morphology of PC12 cells in the absence of NGF. Additionally, other vibsane-type diterpenoids such as 7-membered and 11-membered ring subtypes have not been so far found to show neurotrophic properties in PC12 cells.




Figure 14. Morphology of PC12 cells under treatments of neovibsanin (**86**), neovibsanin A (**62**) and neovibsanin B (**63**)

PC12 cells were cultured in DMEM / 2% HS + 1% FBS and treated by **A**: NGF 10 ng/mL, **B**: Neovibsanin 40 μ M + NGF 10 ng/mL, **C**: Neovibsanin A 40 μ M + NGF 10 ng/mL, **D**: Neovibsanin B 40 μ M + NGF 10 ng/mL.

Quantitative analysis of the percentage of cells with neurites and the neurite length extending from the cell bodies (Figure 15) showed that neovibsanin (**86**) and neovibsanin A (**62**) significantly increased the percentage of PC12 cells bearing neurites and the neurite length compared with those of NGF-mediated PC12 cells at concentrations ranging from 5 to 40 μ M, and, in the degree of activity, **62** (Figure 15, **C** and **D**) was likely to be less than **86** (Figure 15, **A** and **B**). On the other hand neovibsanin B (**63**) promoted efficiently the neurite outgrowth from of NGF-mediated PC12 cells in a dose-dependent manner at concentrations from 10 to 40 μ M (Figure 15, **E** and **F**). In comparison of the percentage of cells with neurites and the average neurite lengths (Figure 16), neovibsanin B (**63**) seemed to be a more potent NGF-potentiator among three compounds. This result consists with morphological evaluation. It is assumed from these results that a stereochemistry on the acetal carbon may be related with affecting neurite outgrowth activity.




Figure 15. Neurite outgrowth-promoting activities of neovibsanin, neovibsanin A, and neovibsanin B in PC12 cells

PC12 cells were cultured in DMEM / 2% HS + 1% FBS with or without 10 ng/mL NGF and different concentrations of neovibsanin, neovibsanin A, and neovibsanin B for 48 h. PC12 cells were fixed and quantified for the percentage of cells bearing neurites and the primary neurite length. Over 40 fields were randomly selected under microscope for analysis of the percent of cells with neurites. At least 200 cells were selected for calculating the neurite length. Data were expressed as means $\pm$ SE. *** $P < 0.001$ compared with NGF only by one-way ANOVA followed by Bonferroni post hoc means comparison. ### $P < 0.001$ vs. control by Student's t-test. **A, B:** neovibsanin, **C, D:** neovibsanin A, **E, F:** neovibsanin B.




Figure 16. Comparison of neurite outgrowth-promoting activities of neovibsanin, neovibsanin A, and neovibsanin B in PC12 cells

The method was the same as that in **Figure 15**. Data were expressed as means $\pm$ SE. Difference between groups was tested with Student's t-test. *** $P < 0.001$ compared with NGF only.

4. Synthesis of neovibsanin B

These unique molecular architectures and significant biological activities have strongly motivated organic chemists to devote their efforts to the syntheses of the vibsane-type diterpenoids. So far, the vibsane-type diterpenoids whose total syntheses have been achieved are only three molecules, i.e. ($\pm$)-2-*O*-methylneovibsanin H (**68**),⁴⁵ ($\pm$)-neovibsanin B (**63**),⁴⁶ and ($\pm$)-vibsanin E (**16**).⁴⁷ From a synthetic point of view, the stereocontrol in the successive stereogenic centers involved in these diterpenoids has been challenging. Williams's pioneering synthetic studies have addressed the issue of diastereoselective creation of the stereocenters involved in vibsane natural products. In fact, through many approaches toward the total syntheses of these molecules, the synthetic efforts have resulted in formation of diastereomers of the natural products (Figure 17), i.e. (6*S*)-vibsanin F (**3a**),¹² ($\pm$)-5,10-bis-*epi*-vibsanin E (**16a**),⁴⁸ ($\pm$)-5,14-bis-*epi*-spirovibsanin A (**82a**)⁴⁹, and

($\pm$)-4,5-bis-*epi*-neovibsanins A (**62a**) and B (**63a**).⁵⁰





Figure 17. Synthesized diastereomers of vibsanine family and neovibsanin B (**63**)

This review is focused on the synthesis of neovibsanin B (**63**), which is not only a significant neurotrophic mimic but also the most challenging molecule among vibsanine natural products.


In 2009, Imagawa and Nishizawa reported the first synthesis of ($\pm$)-neovibsanin B (**63**).⁴⁶ They employed an intramolecular Diels-Alder reaction of **91** at 200 °C in dimethyl imidazolidinone (DMI) as a solvent for constructing the core cyclohexenone ring of neovibsanin, leading to a mixture of **92a** and **92b** (9:1) in 58% yield. DMI plays a crucial role in accelerating this reaction rate and thus makes it suitable for scale-up. Further manipulation of Diels-Alder adducts **92a** and **92b** involves introduction of a hydroxymethyl group by Baylis-Hillman reaction with formaldehyde to provide the key intermediate **95** (Scheme 9). It should be noted that 1,2-addition of nucleophiles to the C-4 ketone was dominated by addition of the less hindered undesired face to afford exclusively products having the undesired stereochemical disposition at C-4.^{45,50,55} Imagawa and Nishizawa overcame this steric drawback by devising tactic of using the oxygen of 2,4-dimethoxybenzyl (2,4-DMPM) group at C-10 to coordinate with the organolithium reagent and deliver the propargyl group from the same face. Reaction of excess lithio ethylpropiolate **96** with a toluene solution of **95** at -78 °C successfully proceeded to give rise to the



Scheme 9. Reagents and conditions: a) $(\text{COCl})_2$, benzene, reflux; b) $\text{TBSOCH}=\text{CHCH}=\text{CH}_2$, MeLi , CH_2Cl_2 , DME , -20°C , 79%; c) DMI , 200°C , 58%; d) DIBAL , THF , -70°C to rt , 89%; e) Bu_2SnO , toluene, reflux, and then $2,4\text{-DMPMCl}$, TBAI , toluene, reflux; f) Dess-Martin reagent, CH_2Cl_2 , 0°C , 70%; g) Bu_3P , HCHO , aq. $\text{MeOH}/\text{CHCl}_3$, rt , 84%; h) TBSCl , imidazole, CH_2Cl_2 , 0°C , 99%.

adduct **97** with the correct stereochemistry in 87% yield as a single diastereomer. 1,2-Addition of **96** to the C-4 ketone in **95** was completely controlled by the coordination of the two oxygen atoms of 2,4-DMPM group with **96**, which is shown in Figure 18, to give **97** having the desired β -configuration at C-4. The triple bond of **97** was reduced with Red-Al to the α,β -unsaturated ester **98**, which was in turn treated with TBAF for the deprotection of the TBS group, thereby triggering the subsequent Michael addition and lactonization to give rise to a tricyclic lactone **99** having the desired stereochemistry in good yield. The Deprotection of 2,4-DMPM in **99** by DDQ oxidation was troublesome due to the acidity of *in situ* formed DDQH . To avoid acidic conditions, this oxidation was carried out in a two phase system of CH_2Cl_2 and NaCl saturated-phosphate buffer to give a desired alcohol, which was protected again as the TBS group, giving rise to **100** in good yield. The resulting **100** was reacted with Tebbe reagent, and then treated with PPTS in methanol afforded a mixture of **102a** and **102b** (1:4.5), which were readily separated by HPLC. The major **102b** was converted to the aldehyde **103**, which was treated with KHMDS to generate a potassium enolate. This was *in situ* trapped with 3,3-dimethylacryloyl chloride completing the first total synthesis of $(\pm)$ -neovibsanin B (**63**).

Recently, we reported efficient construction of the chiral all-carbon quaternary center with a vinyl moiety that would permit post-functional group manipulation by the conjugate addition of lithium divinyl cuprate to (4*S*,2'*E*)-3-(6'- TBDPS -3'-methylhex-2'-enoyl)-4-phenyloxazolidin-2-one (**115**), and demonstrate that this method provides a versatile chiral quaternary carbon source **117** for the synthesis of natural products by its use to the synthesis of (+)-bakuchiol (Scheme 11).⁵¹



Scheme 10. Reagents and conditions: a) Red-Al, THF, -78°C , 87%; b) TBAF, THF, rt, 87%; c) DDQ, CH_2Cl_2 /phosphate buffer, NaCl, 0°C , 83%; d) TBSCl, imidazole, 0°C to rt, 99%; e) Tebbe reagent, pyridine, THF-toluene; f) PPTS, MeOH, 0°C , 91%; g) TBAF, THF, rt, 99%; h) SO_3 /pyridine, Et_3N , DMSO, rt, 89%; i) KHMDS, THF, then 3,3-dimethylacryloyl chloride, -78°C , 60%.






Figure 18. Chelated control of the 2,4-DMPM group with **96**



Scheme 11. Enantioselective construction of the chiral all carbon quaternary center at C-11




Scheme 12. Reagents and conditions: a) 30% H_2O_2 , LiOH , $\text{THF-H}_2\text{O}$, 0°C ; b) EtOH , EDC , DMAP , CH_2Cl_2 , rt ; c) LiAlH_4 , THF , 0°C ; d) PCC , celite, CH_2Cl_2 , 0°C ; e) CBr_4 , PPh_3 , CH_2Cl_2 , 0°C ; f) $n\text{-BuLi}$, THF , -78°C , then $(\text{CH}_2\text{O})_n$, rt ; g) Bu_3SnH , AIBN , THF , reflux; h) I_2 , CH_2Cl_2 , 0°C ; i) TBSCl , DMAP , Et_3N , CH_2Cl_2 , rt .

We have decided to apply this methodology to create the C-11 chiral quaternary carbon involved in vibsanine natural products. As the first target, we selected the Imagawa-Nishizawa intermediate **95** that is the core framework of neovibsanine natural products. The asymmetric 1,4-addition reaction of

(CH₂=CH)₂Cu(CN)Li₂ to **118** bearing (*R*)-4-phenyl-2-oxazolidinone was employed to give **119** as a diastereomeric mixture of 95 (11*S*):5 (11*R*) in good yield. Each diastereomer was readily separated by silica-gel chromatography. The optically pure (11*S*)-**119** was converted to (2*Z*,11*S*)-**122** according to the procedures outlined in Scheme 12.

Previously, we reported that the modified Negishi palladium(0)-catalyzed carbonylative cyclization of (±)-**122** provided the cyclohexene-1-one derivative (±)-**125**, which corresponds to the cyclohexene ring of neovibsanin.⁵² We examined this reaction in detail (Table 1). First, the reaction was performed using 5 mol % PdCl₂(PPh₃)₂ and Et₃N (1.5 equiv) in MeCN/ PhH (1:1) containing 4 equiv of MeOH at 100 °C in an autoclave, which gave rise to the desired diastereomeric mixture of **123** in 11% yield along with ca. 50% of **125** containing a small amount of **124** (6%) (Table 1, entry 1). On the other hand, the addition of an excess amount (48 equiv) of MeOH to this reaction system dramatically increased the yield of **123** to 54%, contaminated with 2% of the noncyclic ester **124** (entry 2). The use of high pressure (8 MPa) was found to be ineffective at suppressing the generation of **124** (entry 3), but low temperature (60 °C) was able to decrease the generation of **124** (entry 4). After several trials, we found that the following reaction

Table 1. Negishi's Pd(0)-Catalyzed Cyclic Carbopalladation-Carbonylative Tandem Reaction of (2*Z*,11*S*)-**122**




entry	base (1.5 equiv)	solvent	MeOH (equiv)	CO (MPa)	temp. (°C)	123 (10 <i>R</i> :10 <i>S</i>) ^a	122	124	125 (%)
1	Et ₃ N	MeCN/PhH (1:1)	4	4	100	11 (1.1:1)	0	6	52
2	Et ₃ N	MeCN/PhH (1:1)	48	4	100	54 (2.4:1)	10	2	0
3	Et ₃ N	MeCN/PhH (1:1)	48	8	100	41 (2.3:1)	9	12	0
4	Et ₃ N	MeCN/PhH (1:1)	48	4	60	49 (2.7:1)	13	0	21
5	Et ₃ N	MeCN/PhH (1:1)	24	4	60	69 (2.6:1)	14	0	0
6	Et ₃ N	1,4-dioxane	4	4	100	0	0	0	90
7	Et ₃ N	MeOH	-	4	100	6 (1.4:1)	13	4	52
8	K ₃ PO ₄	MeCN/PhH (1:1)	4	4	100	16 (1.4:1)	18	0	3
9	<i>i</i> -Pr ₂ NEt	MeCN/PhH (1:1)	4	4	100	0	0	0	85
10	DABCO	MeCN/PhH (1:1)	4	4	100	24 (1.6:1)	0	9	0

^a Ratio was determined by ¹H NMR spectroscopy in CDCl₃ (300 MHz).

conditions; 24 equiv of MeOH, 4 MPa CO, temperature of 60°C, led to the formation of **123** alone in *ca.* 70% yield as a diastereomeric mixture (10*R*:10*S* = 2.6:1) (entry 5). Each diastereomer of **123** was readily separated by silica gel column chromatography. It should be noted that **125** was exclusively generated in high yield when 1,2-dioxane was used as solvent (entry 6).

With (10*R*,11*S*)-**123** in hand, we focused on the last few steps for the synthesis of Imagawa-Nishizawa's intermediate **95** (Scheme 13). Treatment of (10*R*,11*S*)-**123** with *n*-Bu₄NF containing acetic acid gave **126**, and the resultant hydroxy group was oxidized by Swern oxidation to its aldehyde, which was subjected to Wittig olefination to give the dimethyl olefin **127** in 69% yield over two steps. Reduction of **127** with DIBAL-H provided the cyclic hemiacetal **128** and diol **129** in 29 and 26% yields, respectively. The cyclic hemiacetal **128** was reduced with NaBH₄ to give **129**.



Scheme 13. Reagents and conditions: a) *n*-Bu₄NF, AcOH, THF, rt; b) (COCl)₂, DMSO, -78°C to 10°C, then Et₃N; c) Me₂CHP⁺Ph₃I⁻, *n*-BuLi, THF, 0°C; d) DIBAL-H, CH₂Cl₂, -78°C; e) NaBH₄, EtOH, rt; f) 2,4-DMPM-trichloroacetoimide, 10 mol% CSA, CH₂Cl₂, -20°C; g) Dess-Martin periodinane, CH₂Cl₂, rt.

The selective protection of the primary alcohol in **129** using the reaction conditions, 2,4-DMPM-trichloroacetoimide in the presence of 10 mol % CSA gave rise to the desired 2,4-DMPM-ether **130** in 45% yield. Finally Dess-Martin oxidation of **130** afforded the Imagawa-Nishizawa's intermediate (+)-**95** as an optically active form ($[\alpha]_D^{20} +20.1$ (c 1.05, MeOH)) in 95% yield. Thus, the first enantiocontrolled formal synthesis of (+)-neovibsanin B was accomplished.⁵³

CONCLUSION

Since Prof. Kawazu's first report in 1980, over 80 vib sane-type diterpenoids have been found, and the new term of "Vib sane" has now become accepted. These diterpenoids not only show a rich structural diversity, but also occur specifically in a few *Viburnum* species. Thus, they are very interesting natural products from chemical and taxonomic points of view, and moreover, their chemical diversity makes them a valuable chemical library. As neovibsanins A and B have been found to exhibit interesting neurotrophic activity, it is expected that new biological activities will be discovered among the vib sane-type diterpenoids. Recently, vib sane-type diterpenoids have attracted much attention from organic chemists due to their unique structures and important biological activities.⁵⁴⁻⁶⁰ We hope that this review has stimulated much attention in synthetic studies of these diterpenoids and that comprehensive reviews of synthetic studies of the vib sane-type diterpenoids will appear in the near future.

ACKNOWLEDGEMENTS

We thank our colleagues for their dedication toward these vib sane projects, whose names are listed in the literature cited in references. These works were supported by Grant-in-Aids for Scientific Research from the Ministry of Education, Culture, Sports, and Technology of Japan and the Open Research Fund from the Promotion and Mutual Aid Corporation for Private School of Japan.

REFERENCES

1. R. C. Winkworth, *Am. J. Botany*, 2005, **92**, 653.
2. M. Fukuoka and M. Hotta, "*Useful Plants of the World*", ed. by M. Hotta, K. Ogata, A. Nitta, K. Hosikawa, M. Yanagi, and Yamazaki, K., Hebonsha, Tokyo, 1989, 1089.
3. A. M. Schevallier, "*The Encyclopedia of Medicinal Plants*", ed. by D. Kinddersly, London, 1966, 148.
4. J. L. Swerdlow, "*Nature's Medicine*", National Geographic Society, New York, 2000, 388.
5. L. Q. Wang, Y. G. Chen, J. J. Xu, Y. L. Lin, X. M. Li, and Y. Zhao, *Chemistry & Biodiversity*, 2008, **5**, 1879.
6. Y. H. Kuo, *the Formosan Science*, 1992, **45**, 99.
7. K. Kawazu, *Agri. Biol. Chem.*, 1980, **44**, 1367.

8. K. Fukuyama, Y. Katsube, and K. Kawazu, *J. Chem. Soc., Perkin Trans.*, 1980, 44.
9. J. R. Hanson, *Nat. Prod. Rep.*, 2000, **17**, 165.
10. Y. Fukuyama, H. Minami, K. Takeuchi, M. Kodama, and K. Kawazu, *Tetrahedron Lett.*, 1996, **37**, 6767.
11. Y. Fukuyama, H. Minami, S. Takaoka, M. Kodama, K. Kawazu, and H. Nemoto, *Tetrahedron Lett.*, 1997, **38**, 1435.
12. H. Yuasa, G. Makado, and Y. Fukuyama, *Tetrahedron Lett.*, 2003, **44**, 6235.
13. Y. Gao, R. M. Hanson, J. M. Klunder, S. Y. Ko, H. Masamune, and K. B. Sharpless, *J. Am. Chem. Soc.*, 1987, **109**, 5765.
14. J. Tsuji, "Handbook of Organopalladium Chemistry for Organic Synthesis", ed. by E. Negishi and A. de. Meijere, John Wiley & Sons, Inc., New York, 2002, Vol. 2, 39.
15. A. H. El-Gamal, S-K. Wang, and C-Y. Duh, *J. Nat. Prod.*, 2004, **67**, 333.
16. Y.-H. Shen, C. V. S. Prakash, L.-T. Wang, C.-T. Chien, and C.-H. Hung, *J. Nat. Prod.*, 2002, **65**, 1052.
17. H. Minami, S. Anzaki, M. Kubo, M. Kodama, K. Kawazu, and Y. Fukuyama, *Chem. Pharm. Bull.*, 1998, **46**, 74.
18. Y.-C. Shen, C.-L. Lin, S.-C. Chien, A. T. Khalil, C.-L. Ko, and C.-H. Wang, *J. Nat. Prod.*, 2004, **67**, 74.
19. Y. Fukuyama, unpublished data.
20. Y. Fukuyama, H. Minami, A. Matsuo, M. Kitamura, M. Akizuki, M. Kubo, and M. Kodama, *Chem. Pharm. Bull.*, 2002, **47**, 295.
21. C.-Y. Duh, A. H. El-Gamal, and S.-K. Wang, *Tetrahedron Lett.*, 2003, **44**, 9321.
22. M. Kubo, I.-S. Chen, H. Minami, and Y. Fukuyama, *Chem. Pharm. Bull.*, 1999, **47**, 295.
23. Y. Fukuyama, H. Minami, M. Kagawa, M. Kodama, and K. Kawazu, *J. Nat. Prod.*, 1999, **62**, 37.
24. Y. Fukuyama, M. Morisaki, Y. Minoshima, H. Minami, Y. Takahashi, and Y. Asakawa, *Lett. Org. Chem.*, 2004, **1**, 189.
25. Y. Fukuyama, M. Kubo, T. Fuji, A. Matsuo, Y. Minoshima, H. Minami, and M. Morisaki, *Tetrahedron*, 2002, **58**, 10033.
26. M. Kubo, H. Minami, E. Hayashi, M. Kodama, K. Kawazu, and Y. Fukuyama, *Tetrahedron Lett.*, 1999, **40**, 6261.
27. Y. Fukuyama, M. Kubo, H. Minami, H. Yuasa, A. Matsuo, T. Fujii, M. Morisaki, and K. Harada, *Chem. Pharm. Bull.*, 2005, **53**, 72.
28. Y. Fukuyama, H. Fujii, H. Minami, H. Takahashi, and M. Kubo, *J. Nat. Prod.*, 2006, **69**, 1098.
29. M. Kubo, T. Fujii, H. Hioki, M. Tanaka, Y. Kawazu, and Y. Fukuyama, *Tetrahedron Lett.*, 2001, **42**,

- 1081.
30. M. Kubo, Y. Minoshima, D. Arimoto, H. Minami, K. Harada, H. Hioki, and Y. Fukuyama, *Heterocycles*, 2009, **77**, 539.
31. F. Mohamadi, N. G. Richards, E. C. Guida, R. Liskamp, M. Lipton, C. Cafui, G. Chang, T. Hendrickson, and W. C. Still, *J. Comput. Chem.*, 1990, **11**, 440.
32. Y. C. Shen, C. V. S. Prakasha, L. T. Wang, and C. T. Chien, *J. Chin. Chem. Soc.*, 2003, **50**, 297.
33. W. M. Cowan, *Annu. Rev. Neurosci.*, 2001, **24**, 551.
34. P. Li, K. Matsunaga, T. Yamakuni, and Y. Ohizumi, *Eur. J. Pharmacol.*, 2000, **406**, 203.
35. R. D. Brinton and R. S. Yamazaki, *Pharm. Res.*, 1998, **15**, 386.
36. L. A. Greene and A. S. Tischler, *Proc. Natl. Acad. Sci. U. S. A.*, 1976, **73**, 2424.
37. W. Tang, M. Kubo, K. Harada, H. Hioki, and Y. Fukuyama, *Bioorg. Med. Chem. Lett.*, 2009, **19**, 882.
38. (a) S. Tsubuki, H. Kawasaki, Y. Saito, N. Miyashita, M. Inomata, and S. Kawashima, *Biochem. Biophys. Res. Commun.*, 1993, **196**, 1195; (b) S. Tsubuki, Y. Saito, M. Tomioka, H. Ito, and S. Kawashima, *J. Biochem.*, 1996, **119**, 572.
39. P. J. Middlemiss, A. J. Glasky, M. P. Rathbone, E. Werstuik, S. Hindley, and J. Gysbers, *Neurosci. Lett.*, 1995, **199**, 131.
40. A. Pradines, M. Magazin, P. Schiltz, G. L. Fur, D. Caput, and P. Ferrara, *J. Neurochem.*, 1995, **64**, 1954.
41. W. G. R. Angus and M. L. Contreras, *Neurosci. Lett.*, 1995, **191**, 23.
42. Y. Kishimoto, S. Maeda, and Y. Fukuyama, The 126th Annual Meeting of Pharmaceutical Society of Japan, Sendai, 2006.
43. M. Kubo, Y. Kishimoto, K. Harada, H. Hioki, and Y. Fukuyama, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 2566.
44. D. Vaudry, P. J. S. Stork, P. Lazarovici, and L. E. Eiden, *Science*, 2002, **296**, 1648.
45. A. P.-J. Chen and C. M. Williams, *Org. Lett.*, 2008, **10**, 3441.
46. H. Imagawa, H. Saijo, T. Kurisaki, H. Yamamoto, M. Kubo, Y. Fukuyama, and M. Nishizawa, *Org. Lett.*, 2009, **11**, 1253.
47. B. D. Schwartz, J. R. Denton, H. M. L. Davis, and C. M. Williams, *Aust. J. Chem.*, 2009, **62**, 980.
48. H. M. L. Davis, Ø. Loe, and D. G. Stafford, *Org. Lett.*, 2005, **7**, 5561.
49. (a) M. J. Gallen and C. M. Williams, *Org. Lett.*, 2008, **10**, 713; (b) M. J. Gallen and C. M. Williams, *Eur. J. Org. Chem.*, 2008, **27**, 4697.
50. A. P.-J. Chen, C. C. Müller, H. M. Cooper, and C. M. Williams, *Org. Lett.*, 2009, **11**, 3758.
51. T. Esumi, H. Shimizu, A. Kashiya, C. Sasaki, M. Toyota, and Y. Fukuyama, *Tetrahedron Lett.*, 2008, **49**, 6846.

52. T. Esumi, M. Zhao, T. Kawakami, M. Fukumoto, M. Toyota, and Y. Fukuyama, *Tetrahedron Lett.*, 2008, **49**, 2692.
53. T. Esumi, T. Mori, M. Zhao, M. Toyota, and Y. Fukuyama, *Org. Lett.*, 2010, **12**, 888.
54. B. D. Schwartz, J. R. Denton, Y. Lian, H. M. L. Davies, and C. M. Williams, *J. Am. Chem. Soc.*, 2009, **131**, 8329.
55. G. Mehta and B. A. Bhat, *Tetrahedron Lett.*, 2009, **50**, 2474.
56. J. Nikolai, Ø. Loe, P. M. Dominiak, O. O. Gerlitz, J. Autchbach, and H. M. L. Davis, *J. Am. Chem. Soc.*, 2007, **129**, 10763.
57. A. Srikrishna, V. H. Paradeshi, and G. Satyanarayana, *Tetrahedron: Asymmetry*, 2008, **19**, 1984.
58. B. D. Schwartz, C. M. Williams, and P. V. Bernhardt, *Beilstein J. Org. Chem.*, 2008, **4**, 34.
59. B. D. Schwartz, J. R. Denton, Y. Lian, H. M. L. Davis, and C. M. Williams, *J. Am. Chem. Soc.*, 2009, **131**, 8329.
60. B. D. Schwartz, J. R. Denton, P. V. Bernhardt, H. M. L. Davis, and C. M. Williams, *Synthesis*, 2009, 2840.
-



Yoshiyasu Fukuyama received his undergraduate degree in chemistry from Osaka City University in 1970, and his Ph.D. degree from the same institute in 1975 under the supervision of Professor Takashi Kubota. He then spent three years as a postdoctoral fellow with Professor James D. White at Oregon State University (Corvallis, Oregon, USA) from 1975 to 1978. In 1978, he moved to the Institute of Natural Products Chemistry at Otsuka Pharmaceutical Co. Ltd. (Tokushima, Japan), where his studies centered on natural products chemistry. In 1988, he was appointed as an Associate Professor at the Faculty of Pharmaceutical Sciences in Tokushima Bunri University, where he has been working as a Professor since 1995. He is a recipient of Tokushima News Paper Award in 2006. His current research interests lie in chemistry and biology focusing on neurotrophic natural products and his dream is to contribute his basic research to development of drugs for treatment of neurodegenerative diseases.



Miwa Kubo studied Natural Products Chemistry at Tokushima Bunri University. She was appointed as a research assistant of the Faculty of Pharmaceutical Sciences, Tokushima Bunri University in 2000, and obtained her PhD degree in 2007. She is recently promoted as a lecture in 2010, and her research interests are focused on search and chemical biology of neurotrophic natural products.



Tomoyuki Esumi received his B. S. degree from Tokushima Bunri University (Tokushima, Japan) in 1993 and his PhD degree from Nagasaki University (Nagasaki, Japan) in 1998 under the supervision of Prof. Susumi Hatakeyama and then joined the research group of Prof. Yoshito Kishi in Harvard University (MA, USA) as a postdoctoral fellow. He was appointed as a research assistant at Nagasaki University in 1999 and then moved to Tokushima Bunri University as a Lecturer in 2003. His research interests are focused on the total synthesis of biologically and structurally interesting natural products and the development of stereoselective synthetic organic reactions.



Kenichi Harada received his undergraduate degree in pharmaceutical science from Tokushima Bunri University in 2001, and his Ph.D. degree from the same institute in 2006 under the supervision of Professor Yoshiyasu Fukuyama. He was appointed as a research assistant at the Faculty of Pharmaceutical Sciences, Tokushima Bunri University in 2006, where he has been working as an assistant professor since 2007. His research interests lie in the development of new synthetic methodologies using transition metal catalyzed reactions.



Hideaki Hioki received his B. S. degree in chemistry from Tohoku University in 1986 and his M. S. degree from the same university in 1988. He moved to Faculty of Pharmaceutical Sciences in Tokushima Bunri University as a research assistant, where he studied synthetic organic chemistry under the direction of Prof. Sho Ito. After he received Ph. D. degree from Tokushima Bunri University in 1994, he spent one and a quarter years in Columbia University (New York, USA), as a postdoctoral fellow with Prof. W. Clark Still. He studied dynamic combinatorial chemistry there. After he came back to Japan, he was promoted as an Associate Professor at the Faculty of Pharmaceutical Sciences in Tokushima Bunri University working with Prof. Mitsuaki Kodama in 1999. Then he joined Prof. Yoshiyasu Fukuyama group in 2006. He received PSJ (Pharmaceutical Society of Japan) Chugoku-Shikoku Branch Award for Young Scientists in 2004. His current research interests are synthetic organic chemistry and supramolecular chemistry combined with combinatorial chemistry.